{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037552","form_type":"8-K","ticker":null,"cik":"0001771917","company_name":"Karuna Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.176871+00:00","generated_at":"2026-06-12T09:00:11.559612+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Karuna reports Q2 net loss $103.2M; CFO transition, NDA for KarXT on track","bullets":["Net loss $103.2M vs $64.9M a year ago; R&D $92.5M, G&A $27.4M.","Cash $1.4B as of June 30, 2023, sufficient to fund operations through 2026.","CFO Troy Ignelzi to depart Sept 29, 2023; succeeded by Jason Brown (SVP Finance).","Jason Brown receives base salary $505,000, target bonus 45%, equity grants $1.6M total.","NDA submission for KarXT in schizophrenia on track for Q3 2023; potential launch H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037552","json":"https://secwatch.observer/filing/0000950170-23-037552.json","markdown":"https://secwatch.observer/filing/0000950170-23-037552.md","text":"https://secwatch.observer/filing/0000950170-23-037552.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771917/000095017023037552/0000950170-23-037552-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771917/000095017023037552/krtx-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:00:11.559612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3bfa074b72a82823a70ea356c183e3f99f84ba59","claim":"Karuna Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income net loss of $103.2 million.","evidence_excerpt":"On August 3, 2023, Karuna Therapeutics, Inc. (the \"Company\") announced its financial results and general corporate updates for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771917/000095017023037552/0000950170-23-037552-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"net loss of $103.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"26913852b5","claim":"Jason Brown was appointed as Chief Financial Officer at Karuna Therapeutics, Inc..","evidence_excerpt":"the Company announced that the Board of Directors of the Company has appointed Jason Brown to succeed Mr. Ignelzi as Chief Financial Officer of the Company, effective as of September 29, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771917/000095017023037552/0000950170-23-037552-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"6d59961ae4","claim":"Troy Ignelzi departed as Chief Financial Officer at Karuna Therapeutics, Inc..","evidence_excerpt":"the Company and Troy Ignelzi, the Company's Chief Financial Officer, mutually agreed that Mr. Ignelzi will depart from the Company effective September 29, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771917/000095017023037552/0000950170-23-037552-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"depart"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}